A noncomparative randomized phase II study of two dose levels of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC): A DOD/PCCTC trial.

被引：0
|
作者：
Antonarakis, E. S.
Heath, E. I.
Smith, D. C.
Rathkopf, D. E.
Blackford, A. L.
Danila, D. C.
King, S.
Frost, A.
Carducci, M. A.
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Karmanos Canc Inst, Detroit, MI USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA
[5] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4532
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4532
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II study of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) and progression on enzalutamide (enza).
    Teply, Benjamin A.
    Wang, Hao
    Sullivan, Rana
    Rifkind, Irina
    Bruns, Ashley
    Decarli, Morgan
    Sinibaldi, Victoria J.
    Pratz, Caroline F.
    Luo, Jun
    Carducci, Michael Anthony
    Paller, Channing Judith
    Antonarakis, Emmanuel S.
    Eisenberger, Mario A.
    Denmeade, Samuel R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Werner, Lillian
    Erlander, Mark G.
    Ridinger, Maya
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [33] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [34] Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)
    Graff, Julie Nicole
    Cheng, Heather H.
    Vuky, Jacqueline
    Alumkal, Joshi J.
    Kreitner, Dustin
    Petreaca, Delia
    Grivas, Petros
    Schweizer, Michael Thomas
    Higano, Celestia S.
    Chen, Yiyi
    Yu, Evan Y.
    Beer, Tomasz M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [35] Phase I/II trial of enzalutamide (Enz) plus mifepristone (Mif) for metastatic castration-resistant prostate cancer (mCRPC)
    Serritella, Anthony
    Shevrin, Daniel H.
    Heath, Elisabeth I.
    Wade, James Lloyd
    Martinez, Elia
    Karrison, Theodore
    Stadler, Walter Michael
    Szmulewitz, Russell Zelig
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [36] Phase II trial of carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following androgen pathway inhibitors.
    Naik, Gurudatta
    Bae, Sejong
    De Shazo, Mollie R.
    Dixon, Pam
    Merritt, Lynn
    Sartor, A. Oliver
    Schnell, Frederick M.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [37] Randomized phase II study of abiraterone acetate maintenance in combination with docetaxel after disease progression to abiraterone acetate in metastatic castration-resistant prostate cancer (mCRPC): ABIDO SOGUG trial.
    Climent, Miguel Angel
    Sanchez, Alfredo
    Mellado, Begona
    Santander, Carmen
    Cassinello, Javier
    Isabel Saez, M.
    Lazaro Quintela, Martin
    Maroto Rey, Jose Pablo
    Mendez-Vidal, Maria Jose
    del Alba, Aranzazu Gonzalez
    Grande, Enrique
    Duran, Ignacio
    Esteban, Emilio
    Font, Albert
    Arranz Arjia, Jose Angel
    Puente, Javier
    Castellano, Daniel E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] A randomized phase I/II study to examine the contribution of carboplatin to cabazitaxel for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) with and without anaplastic features
    Corn, Paul Gettys
    Tu, Shi-Ming
    Zurita, Amado J.
    Araujo, John C.
    Pagliaro, Lance C.
    Logothetis, Christopher
    Aparicio, Ana
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [39] CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial.
    De Bono, Johann S.
    Pantel, Klaus
    Efstathiou, Eleni
    Sternberg, Cora N.
    Castellano, Daniel
    Fizazi, Karim
    Tombal, Bertrand
    Wulfing, Christian
    Schonhoft, Joseph D.
    Gill, Audrey
    Chu, Lincy
    Wenstrup, Rick
    Ozatilgan, Ayse
    Geffriaud-Ricouard, Christine
    Mace, Sandrine
    De Wit, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [40] Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael Thomas
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
12345